ENLV vs. XBIT, ENTX, IVVD, CHRS, CRDL, IMUX, ZNTL, KYTX, ORMP, and ANIX
Should you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include XBiotech (XBIT), Entera Bio (ENTX), Invivyd (IVVD), Coherus BioSciences (CHRS), Cardiol Therapeutics (CRDL), Immunic (IMUX), Zentalis Pharmaceuticals (ZNTL), Kyverna Therapeutics (KYTX), Oramed Pharmaceuticals (ORMP), and Anixa Biosciences (ANIX). These companies are all part of the "pharmaceutical products" industry.
Enlivex Therapeutics vs.
XBiotech (NASDAQ:XBIT) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, community ranking, institutional ownership and profitability.
Enlivex Therapeutics has a consensus target price of $10.00, indicating a potential upside of 939.39%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than XBiotech.
XBiotech received 257 more outperform votes than Enlivex Therapeutics when rated by MarketBeat users. However, 81.08% of users gave Enlivex Therapeutics an outperform vote while only 69.82% of users gave XBiotech an outperform vote.
55.7% of XBiotech shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 33.1% of XBiotech shares are held by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
XBiotech's return on equity of -15.99% beat Enlivex Therapeutics' return on equity.
XBiotech has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.
In the previous week, XBiotech and XBiotech both had 1 articles in the media. XBiotech's average media sentiment score of 0.00 equaled Enlivex Therapeutics'average media sentiment score.
XBiotech has higher revenue and earnings than Enlivex Therapeutics. XBiotech is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
XBiotech beats Enlivex Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Enlivex Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enlivex Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ENLV) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy ENLV Stock Free ENLV Stock Alerts